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Abstract 
Background: Arterial stiffness is an independent predictor for vascular diseases. Carotid-femoral pulse wave velocity 
(CFPWV) is a reliable index of arterial stiffness. In the present study, we investigated the possible risk factors involving 
CFPWV in hypertension and diabetes mellitus (DM) subjects.  
Methods: 425 subjects (M/F 168/257) from Shougang Corporation Examination Center were divided into four groups: 
healthy group (n=185), hypertension group (n=135), DM group (n=32), hypertension with DM group (n=73). CFPWV was 
measured by Complior apparatus.  
Keywords: Carotid-femoral pulse wave velocity; Hypertension; Diabetes mellitus  
 
 
 
 
 
 
 
 
Council for Innovative Research 
Peer Review Research Publishing System 
Journal: International Journal of Research in Education methodology 
Vol. 7, No.3 
ijremeditor@gmail.com 
www.ijrem.com 
ISSN 2278-7690                                                           
1196 | P a g e                                A u g u s t  1 4 ,  2 0 1 5  
Results: Our results showed that CFPWV was significantly higher in hypertension subjects with DM than in healthy and 
hypertension group, respectively (12.00+2.57 vs 10.12+2.28 m/s; 12.00+2.57 vs 10.78+2.07 m/s, both p<0.05). CFPWV 
was positively correlated with age, systolic blood pressure (SBP), diastolic blood pressure (DBP), pulse pressure (PP), 
fasting plasma glucose ( FBG), HbA1c, uric acid, Log NT-proBNP and Log Urine Albumin (microalbumin) Excretion [Log 
UAE] in the entire group(r=0.437, 0.410, 0.206, 0.423, 0.210, 0.275, 0.130, 0.135, 0.166, all p<0.05, respectively). 
Multivariate analysis showed that age, body mass index, SBP, PP, FBG were independent associating factors of CFPWV in 
all subjects (β=0.287, p<0.001; β= -0.194, p=0.003; β=0.223, p=0.001; β=0.293, p<0.001; β=0.161, p=0.008; respectively).  
Conclusions: Our present study suggested that CFPWV was significantly higher in hypertension subjects with DM 
compared to healthy and hypertension groups. 
1. Introduction 
Hypertension and diabetes mellitus (DM) are the mostly risk factors of vascular-related diseases such as coronary artery 
diseases, stroke, and peripheral vascular diseases. And arteriosclerosis is the basic path-physiological change of 
hypertension and DM. Both hypertension and DM could cause macro- and micro- vascular complications, such as aortic 
atherosclerosis and retinal artery arteriosclerosis, leading to an increase of arterial wall thickness, endothelial dysfunction 
and calcification, finally leading to an increase of arterial stiffness [1]. Arterial stiffness is a strong predictor of future 
cardiovascular events and all-cause mortality. And it is one of the earliest detectable manifestations of adverse structural 
and functional changes within the vessel wall [2]. Pulse wave velocity (PWV) is considered as the gold standard method of 
arterial stiffness suggested by European Society of Hypertension/European Society of Cardiology guidelines [3]. And our 
previous studies showed that arterial stiffness was positively correlated with pulse pressure and it was increased in 
hypertension patients with left ventricular hypertrophy [4, 5]. Recently, a meta-analysis showed that PWV is a strong 
predictor of future cardiovascular events and all-cause mortality, which revealed that an increase in aortic PWV by 100 cm/s 
corresponded to an age-, sex, and risk factor-adjusted risk increase of 14%, 15%, and 15% in total cardiovascular events, 
cardiovascular mortality, and all-cause mortality, respectively [6]. 
Biomarkers of vascular-related diseases such as homocysteine (Hcy), N-Terminal pro-brain natriuretic peptide 
(NT-proBNP), and urine albumin(microalbumin) excretion have involved the pathophysiological development of 
arteriosclerosis. However, there was little research about CFPWV and biomarkers in hypertension subjects with DM. So our 
present study was to investigate the possible relationship between CFPWV and biomarkers in hypertension subjects with 
DM. 
2. Materials and methods 
2.1 Subjects  
425 subjects (M/F 168/257) from Shougang Corporation Examination Center from January 2012 to December 2013 were 
enrolled into our study. Subjects with coronary artery diseases, heart failure, stroke, renal function impairment, liver function 
impairment, systemic inflammatory diseases, infectious disease or cancer were excluded. They were divided into four 
groups: healthy group (n=185), hypertension group (n=135), DM group (n=32), hypertension with DM group (n=73). 
Hypertension was defined as blood pressure measurement ≥140/90mmHg in three occasions at rest. DM was defined 
according to the 75 g oral glucose tolerance test (OGTT). All participants gave their written informed consent.  
2.2 The assessment of CFPWV 
Arterial stiffness was evaluated by measuring automatic PWV using the Complior apparatus which was used for the 
measurement of PWV widely around the world with great accuracy and reproducibility. The basic principle of PWV 
assessment is that pressure pulse generated by ventricular ejection is propagated along the arterial system at a speed 
determined by elasticity of the arterial wall. Knowing the distance and pulse transit time, the velocity can be calculated. 
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Patients were placed in recumbent position and, after a 10-minute rest, underwent PWV measurement and carotid-femoral 
PWV (CF-PWV) was obtained automatically. Estimation of the distance travelled by the pulse is based on measuring the 
distance between the common carotid artery and the right femoral artery according to previous study. 
2.3 Laboratory measurements 
Blood samples were drawn from an antecubital vein in the morning after overnight fasting and collected into vacuum tubes 
containing EDTA for the measurement of plasma lipid and lipoprotein levels. Fasting plasma glucose (FPG), total 
cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), triglyceride (TG), homocysteine, and hs-C reactive protein 
(hs-CRP) were analyzed by colorimetric enzymatic assays with the use of an autoanalyzer (HITACHI-7170, Hitachi, Tokyo, 
Japan) at the central chemistry laboratory of the Peking University Shougang Hospital. Low-density lipoprotein cholesterol 
(LDL-C) levels were calculated. Urine Albumin(microalbumin) Excretion (UAE) was determined on the 12  hours overnight 
urine samples calculated from the urine albumin concentration, urine volume and collection time at the central chemistry 
laboratory of the Peking University Shougang Hospital. The level of NT-proBNP was measured using the method of 
Bio-directional lateral flow immunoassay (ReLIA) according to the procedure. 
2.4 Statistical analysis 
The differences between groups were analyzed by one-way ANOVA and least-significant difference (LSD). Correlation 
coefficient was done to find linear relation between different variables using Spearman correlation coefficient. Multiple linear 
regressions were used to estimate the coefficients of the linear equation, involving independent variables that affected the 
value of the dependent variables. The values of NT-proBNP and UAE were not in normal distribution, so we made log 
transformation of NT-proBNP and urinary-microalbumin in the present study. Values were shown as mean± SD unless 
stand otherwise. p < 0.05 (2-tailed) was considered statistically significant. 
3. Results 
3.1 Clinical characteristics of the study participants 
The clinical characteristics of study participants are shown in Table 1. Our results showed that the CFPWV was significantly 
higher in hypertension subjects with DM than in healthy and hypertension group, respectively (12.00+2.57 vs 10.12+2.28 
m/s; 12.00+2.57 vs 10.78+2.07 m/s, both p<0.05). And there was significant difference in age, BMI, blood pressure, Hcy 
and Log UAE between these four groups. 
3.2  Pearson correlations between CFPWV and metabolic markers 
Next, we investigated the Pearson correlations between CFPWV and metabolic markers and other variables in the entire 
group. As shown in Table 2, our results showed that CFPWV was positively correlated with age, systolic blood pressure 
(SBP), diastolic blood pressure (DBP), pulse pressure (PP), fasting plasma glucose ( FBG), HbA1c, uric acid, Log 
NT-proBNP and Log UAE in the entire group(r=0.437, 0.410, 0.206, 0.423, 0.210, 0.275, 0.130, 0.135, 0.166, all p<0.05, 
respectively). And there was significant correlation between CFPWV and FBG, uric acid and Log UAE in non-healthy 
subjects (r=0.212, 0.186, 0.200, all p<0.05, respectively). 
3.3  Multiple linear regression analysis 
Multiple linear regressions were used to estimate the coefficients of the linear equation, involving independent variables 
that affected the value of CAVI. As shown in Table 3, our results showed that age, body mass index (BMI), SBP, PP, FBG 
were independent associating factors of CFPWV in all subjects (β=0.287, p<0.001; β= -0.194, p=0.003; β=0.223, p=0.001; 
β=0.293, p<0.001; β=0.161, p=0.008; respectively). BMI and PP were independent associating factors of CFPWV in 
healthy subjects (β= -0.216, p=0.020; β= 0.623, p<0.001; respectively). Age, BMI, SBP, FBG and UA were independent 
associating factors of CFPWV in non-healthy subjects (β=0.251, p=0.002; β= -0.187, p=0.031; β=0.362, p<0.001; β=0.193, 
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p=0.015; β=0.260, p=0.001; respectively). 
4. Discussion 
Our present study showed that CFPWV was significantly higher in hypertension subjects with DM compared to healthy and 
hypertension groups. There was positive correlation between CFPWV and biomarkers. 
An increase of arterial stiffness is not only a pathological status of hypertension and diabetes mellitus (DM) but also a 
strong predictor for the cardiovascular morbidity and mortality caused by these diseases. Pulse wave velocity (PWV) has 
been considered as the golden method of arterial stiffness suggested by European Society of Hypertension/European 
Society of Cardiology guidelines [3]. And many studies have showed the value of PWV in the prediction of vascular-related 
accidents. Kingwell et al reported that large artery stiffness was a major determinant for myocardial ischemic threshold in 
patients with coronary artery disease [7]. In the Rotterdam Study [8], they reported their results that aortic PWV was an 
independent predictor of coronary heart disease and stroke in apparently health subjects, aortic PWV also provided 
additional predictive value above cardiovascular risk factors. Hansen found that PWV was a useful predictor for 
cardiovascular outcomes above and beyond traditional cardiovascular risk factors such as 24-hour mean blood pressure in 
a prospective study of general Danish population [9]. Another prospective study showed that carotid and femoral stiffness 
indices were independently associated with incident cardiovascular events and all-cause mortality [10]. Aortic PWV was 
increasing in patients with diabetes mellitus or end-stage renal disease, indicating a higher arterial stiffness compared with 
health persons [11]. Recent study showed that the level of CFPWV was higher in DM subjects with higher HbA1c [12]. A 
recent review showed that PWV was a marker of cognitive impairment in the elderly subjects [13]. Above research suggest 
that CFPWV is a reliable evaluation index of arterial stiffness. However, these studies focused on research about CFPWV 
in single disease such as DM or coronary artery disease or hypertension, and there was little research about CFPWV in 
hypertension subjects with DM simultaneously and hyperglycemia might exacerbate vascular function in hypertension 
patients. And our present study showed that CFPWV was significantly higher in hypertension subjects with DM compared to 
healthy and hypertension groups. 
Hypertension and DM were important risk factors causing macrovascular or microvascular lesions contributing to an 
increase of PWV.  Microalbuminuria is one of the most common complications of hypertension and DM. NT-proBNP is a 
controregulatory hormone associated with cardiac remodeling. Recent study showed that NT-proBNP  was correlated with 
pulse wave velocity and ankle-brachial index in patients with DM indicating NT-proBNP could be a marker of subclinical 
atherosclerosis [14]. Microalbuminuria is an early indicator of impaired renal function caused by hypertension and The UAE 
increased significantly with the severity of hypertension [15]. And our present study showed that CFPWV was positively 
correlated with Log NT-proBNP and Log UAE in the entire group, and there was significant correlation between CFPWV 
and Log UAE in non-healthy subjects. Baena found that uric acid was significantly associated to CFPWV in an apparently 
healthy population, the similar result to our present study [16]. Another study showed that circulating levels of uridine, 
phenylacetylglutamine, and serine appear strongly correlated with PWV in women [17]. And recent study showed that high 
normal albuminuria was associated with aortic stiffness in DM patients [18]. These results suggested the relationship 
between CFPWV and complications caused by hypertension and DM, similar results to our present study. However, a major 
limitation of our study is its cross-sectional design; another limitation is that the subjects’ numbers of each group were not 
balanced, so large sample and prospective study need to be investigated in future. 
In conclusion, our present study suggested that CFPWV was significantly higher in hypertension subjects with DM 
compared to healthy and hypertension groups. And there was correlation between CFPWV and biomarkers in these 
subjects, more studies should be investigated in future. 
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Table 1  Clinical characteristics in different groups. 
Characterisitic
s 
Healthy 
(N=185) 
Hypertension 
(N=135) 
DM 
(N=32) 
Hypertension 
+ DM (N=73) 
p 
Age (year） 55.95+10.47 59.01+10.58 61.22+9.46* 61.44+10.85* <0.001 
Male/Famale 74/111 54/81 12/30 28/45 0.988 
BMI 24.35+3.43 25.93+3.08 24.89+4.25 25.97+3.38* <0.001 
CFPWV 10.12+2.28 10.78+2.07 11.04+2.47 12.00+2.57*# <0.001 
SBP (mmHg） 128.7+16.2 143.0+19.4*& 130.8+15.8 147.4+18.5*& <0.001 
DBP (mmHg） 80.6+9.6 87.5+11.4*& 80.3+10.3 88.6+10.3*& <0.001 
PP (mmHg） 48.1+10.5 55.4+13.9* 50.7+12.2 58.8+16.0*& <0.001 
FPG (mmol/L) 5.50+0.85 5.54+0.88 7.15+1.72*# 6.60+2.00*# <0.001 
HbA1c % 5.54+0.61 5.55+0.84 6.46+1.00*# 6.71+1.26*# <0.001 
UA 298.17+72.0 314.70+81.60 288.68+68.06 309.01+80.0 0.160 
TC (mmol/L) 5.17+1.10 5.07+1.15 4.82+1.09 4.64+1.30* 0.008 
HDL-C 
(mmol/L) 
1.33+0.35 1.27+0.33 1.26+0.31 1.18+0.26* 0.012 
LDL-C 
(mmol/L) 
3.24+0.89 3.21+0.88 3.00+0.92 2.68+0.94* <0.001 
TG (mmol/L) 1.71+1.39 1.84+1.59 1.76+1.02 1.75+1.17 0.894 
HCY 11.54+5.92 14.31+9.00* 10.09+3.93# 13.98+6.59 0.001 
Log 
NT-proBNP 
2.03+0.40 2.08+0.46 2.14+0.51 2.20+0.27 0.085 
Log UAE 0.57+0.39 0.75+0.55* 0.80+0.59 0.84+0.60* 0.004 
Note: 
* 
vs Normal p<0.05;  
#
  vs Hypertension  p<0.05;  
&
 vs DM p<0.05. BMI: body mass index; SBP: systolic blood 
pressure; DBP: diastolic blood pressure; PP: pulse pressure; FPG: fasting plasma glucose; UA: uric acid; TC: cholesterol; 
LDL-C: low-density lipoprotein cholesterol. HDL-C: high-density lipoprotein cholesterol. TG: triglycerides. UAE: Urine 
Albumin (microalbumin) Excretion , CF-PWV:Carotid-femoral pulse wave velocity. The differences between groups were 
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analyzed by one-way ANOVA and least-significant difference (LSD). Proportions were analyzed by χ
2
 -test. 
Table 2 Spearman correlations between CFPWV and study variables among entire study group, healthy group 
and non-healthy group 
 Entire group 
(N=425) 
Healthy group 
(N=185) 
Non-healthy group 
(N=240) 
r P value r P value r P value 
Age (year） 0.437 <0.001 0.451 <0.001 0.384 <0.001 
BMI -0.014 0.774 -0.109 0.148 -0.029 0.653 
SBP (mmHg） 0.410 <0.001 0.364 <0.001 0.363 <0.001 
DBP (mmHg） 0.206 <0.001 0.122 0.098 0.173 0.008 
PP (mmHg） 0.423 <0.001 0.448 <0.001 0.355 <0.001 
FPG (mmol/L) 0.210 <0.001 0.091 0.221 0.212 0.001 
HbA1c % 0.275 <0.001 0.087 0.307 0.203 <0.001 
UA 0.130 0.008 0.017 0.817 0.186 0.004 
HCY 0.088 0.078 -0.032 0.675 0.105 0.117 
Log NT-proBNP 0.135 0.014 0.160 0.050 0.081 0.282 
Log UAE 0.166 0.004 -0.032 0.736 0.200 0.007 
Note: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; FPG: fasting 
plasma glucose; UA: uric acid; UAE: Urine Albumin (microalbumin) Excretion , CF-PWV:Carotid-femoral pulse wave 
velocity. 
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Table 3 Multiple linear regression analysis for the relationship between CFPWV and study variables among 
entire study group, healthy group and non-healthy group 
 Entire group 
(N=425) 
Healthy group 
(N=185) 
Non-healthy group 
(N=240) 
β P value β P value β P value 
Age (year） 0.287 <0.001 0.178 0.065 0.251 0.002 
BMI -0.194 0.003 -0.216 0.020 -0.187 0.031 
SBP (mmHg） 0.223 0.001 0.050 0.753 0.362 <0.001 
DBP (mmHg） -0.051 0.406 0.029 0.753 0.197 0.114 
PP (mmHg） 0.293 <0.001 0.623 <0.001 -0.267 0.127 
FPG (mmol/L) 0.161 0.008 0.102 0.279 0.193 0.015 
HbA1c % -0.040 0.613 0.033 0.732 -0.005 0.959 
UA 0.139 0.019 0.025 0.788 0.260 0.001 
HCY -0.051 0.406 -0.054 0.547 -0.044 0.592 
Log 
NT-proBNP 
-0.074 0.237 -0.020 0.824 -0.099 0.251 
Log UAE 0.072 0.252 0.082 0.417 0.070 0.395 
Note: BMI: body mass index; SBP: systolic blood pressure; DBP: diastolic blood pressure; PP: pulse pressure; FPG: fasting 
plasma glucose; UA: uric acid; UAE: Urine Albumin (microalbumin) Excretion , CF-PWV:Carotid-femoral pulse wave 
velocity. 
